1844 related articles for article (PubMed ID: 17252575)
81. MRI and PET/CT of patients with bone metastases from breast carcinoma.
Grankvist J; Fisker R; Iyer V; Fründ ET; Simonsen C; Christensen T; Stenbygaard L; Ewertz M; Larsson EM
Eur J Radiol; 2012 Jan; 81(1):e13-8. PubMed ID: 21227614
[TBL] [Abstract][Full Text] [Related]
82. [The value of integrated PET-CT images in 2 lymphoma patients with skeletal localisations].
Geerts MC; Quarles van Ufford HM; Kramer MH; van Waes PF; de Klerk JM
Ned Tijdschr Geneeskd; 2006 Jan; 150(4):204-9. PubMed ID: 16471237
[TBL] [Abstract][Full Text] [Related]
83. Role of FDG PET/CT in staging of recurrent ovarian cancer.
Son H; Khan SM; Rahaman J; Cameron KL; Prasad-Hayes M; Chuang L; Machac J; Heiba S; Kostakoglu L
Radiographics; 2011; 31(2):569-83. PubMed ID: 21415197
[TBL] [Abstract][Full Text] [Related]
84. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
[TBL] [Abstract][Full Text] [Related]
85. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ
Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
[TBL] [Abstract][Full Text] [Related]
86. Interesting image. Correlative imaging with FDG PET-CT and MRI of an unusual recurrence of urothelial cancer in an ileal conduit.
Purandare NC; Dua S; Shah S; Gupta K; Sharma AR; Rangarajan V
Clin Nucl Med; 2010 Jan; 35(1):42-3. PubMed ID: 20026976
[No Abstract] [Full Text] [Related]
87. Multiple cardiac masses and distant metastatic foci in a patient with high grade pleomorphic sarcoma of the heart revealed by follow-up FDG PET/CT.
Uslu L; Asa S; Sager S; Halaç M
Nuklearmedizin; 2014; 53(2):N8-9. PubMed ID: 24777356
[No Abstract] [Full Text] [Related]
88. Clinical applications of PET and PET/CT in pediatric malignancies.
Kumar R; Shandal V; Shamim SA; Halanaik D; Malhotra A
Expert Rev Anticancer Ther; 2010 May; 10(5):755-68. PubMed ID: 20470007
[TBL] [Abstract][Full Text] [Related]
89. Performance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis.
Liu F; Zhang Q; Zhu D; Liu F; Li Z; Li J; Wang B; Zhou D; Dong J
Medicine (Baltimore); 2015 Sep; 94(36):e1462. PubMed ID: 26356700
[TBL] [Abstract][Full Text] [Related]
90. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma.
Rhodes MM; Delbeke D; Whitlock JA; Martin W; Kuttesch JF; Frangoul HA; Shankar S
J Pediatr Hematol Oncol; 2006 May; 28(5):300-6. PubMed ID: 16772881
[TBL] [Abstract][Full Text] [Related]
91. FDG PET/CT of primary bone tumors.
Costelloe CM; Chuang HH; Madewell JE
AJR Am J Roentgenol; 2014 Jun; 202(6):W521-31. PubMed ID: 24848845
[TBL] [Abstract][Full Text] [Related]
92. Fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging of uterine leiomyosarcomas: 2 cases report.
Zhang HJ; Zhan FH; Li YJ; Sun HR; Bai RJ; Gao S
Chin Med J (Engl); 2011 Jul; 124(14):2237-40. PubMed ID: 21933635
[TBL] [Abstract][Full Text] [Related]
93. 18Fluoro-deoxyglucose positron emission tomography evaluation of benign versus malignant osteochondromas: preliminary observations.
Feldman F; Vanheertum R; Saxena C
J Comput Assist Tomogr; 2006; 30(5):858-64. PubMed ID: 16954943
[TBL] [Abstract][Full Text] [Related]
94. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
95. [Combined functional and morphological imaging of sarcomas: significance for diagnostics and therapy monitoring].
Schramm N; Schlemmer M; Rist C; Issels R; Reiser MF; Berger F
Radiologe; 2010 Apr; 50(4):339-48. PubMed ID: 20221579
[TBL] [Abstract][Full Text] [Related]
96. The management of pyothorax-associated lymphoma using 18F-FDG PET/CT.
Ito K; Shida Y; Kubota K; Morooka M; Aruga T; Itami J; Matsuda H
Ann Nucl Med; 2010 Nov; 24(9):649-54. PubMed ID: 20740330
[TBL] [Abstract][Full Text] [Related]
97. FDG PET with contrast-enhanced CT: a critical imaging tool for laryngeal carcinoma.
Chu MM; Kositwattanarerk A; Lee DJ; Makkar JS; Genden EM; Kao J; Packer SH; Som PM; Kostakoglu L
Radiographics; 2010 Sep; 30(5):1353-72. PubMed ID: 20833855
[TBL] [Abstract][Full Text] [Related]
98. Usefulness of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography for staging and evaluation of treatment response in IgG4-related disease: a retrospective multicenter study.
Ebbo M; Grados A; Guedj E; Gobert D; Colavolpe C; Zaidan M; Masseau A; Bernard F; Berthelot JM; Morel N; Lifermann F; Palat S; Haroche J; Mariette X; Godeau B; Bernit E; Costedoat-Chalumeau N; Papo T; Hamidou M; Harlé JR; Schleinitz N
Arthritis Care Res (Hoboken); 2014 Jan; 66(1):86-96. PubMed ID: 23836437
[TBL] [Abstract][Full Text] [Related]
99. First description of the role of ¹⁸F-FDG-PET/CT as compared to CT, MRI to suspect a case of thymoma in a pediatric patient.
Tsuchida T; Kinoshita S; Kawakita A; Yasutomi M; Tanizawa A; Kimura H
Hell J Nucl Med; 2012; 15(1):68-9. PubMed ID: 22413119
[No Abstract] [Full Text] [Related]
100. Post-treatment surveillance of head and neck cancer: pitfalls in the interpretation of FDG PET-CT/MRI.
Meerwein CM; Queiroz M; Kollias S; Hüllner M; Veit-Haibach P; Huber GF
Swiss Med Wkly; 2015; 145():w14116. PubMed ID: 25701645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
